Gong N, Xiao Q, Zhu B, Zhang CY, Wang YC, Fan H, Ma AN, Wang YX (2014) Activation of spinal glucagon-like peptide-1 receptors specifically suppresses pain hypersensitivity
The FDA approved bremelanotide in 2019 to treat hypoactive sexual desire disorder in premenopausal women, though its sometimes used off-label for men experiencing erectile dysfunction
STAT News
Disclosures: Madhumita Premkumar: Nothing to Disclose, Kamal Kajal: Nothing to Disclose, Manhal Izzy: Mallinckrodt: Speaking and Teaching, Bhupendra Sihag: Nothing to Disclose, Ajay Bahl: Nothing to Disclose, Vishesh Kumar: Nothing to Disclose, Ajay Duseja: Nothing to Disclose, Akash Roy: Nothing to Disclose, Sahaj Rathi: Nothing to Disclose, Harish Bhujade: Nothing to Disclose, Rohit Mehtani: Nothing to Disclose, Nipun Verma: Nothing to Disclose, SUNIL TANEJA: Nothing to Disclose, Jasvinder Nain: Nothing to Disclose 2621 PREDICTORS OF TREATMENT FAILURE AND RESISTANCE ASSOCIATED SUBSTITUTIONS IN PATIENTS WITH CHRONIC HEPATITIS C INFECTIONS - HCV ELIMINATION EXPERIENCE FROM THE PUNJAB MODEL IN INDIA Radha Dhiman 1 Madhumita Premkumar 2 Jasvinder Nain 2 Ajay Duseja 2 EkTA Gupta 3 Sahaj Rathi 2 SUNIL TANEJA 2 Surender Singh 1 Akash Roy 1 Anchal Sandhu 2 Prerna Sharma 2 Gagandeep Singh Grover 4 , 1 SGPGIMS, Lucknow, India, 2 PGIMER, Chandigarh, India, 3 ILBS, New Delhi, India, 4 Punjab Governmaent, Punjab Background: The prevalence of HCV is 3.6% in the state of in Punjab, India with an estimated 728,000 viremic chronic hepatitis C (CHC) patients and HCV cure rate the national hepatitis C elimination programme (NVHCP) is 91.6% (Dhiman RK et al, J Hepatol 71(6):1076-1085)
Shi Y, Cui Y, Sun X, et al
doi: 10.2337/db24-262-OR [DOI] [Google Scholar] 83.Amgen announces robust weight loss with maritide in people living with obesity or overweight at 52 weeks in a Phase 2 study
